scholarly journals P298 Referral Patterns And Mortality In A Non-invasive Ventilation (niv) Unit In A Tertiary University Hospital In The Uk

Thorax ◽  
2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. A205-A205
Author(s):  
K. Aldridge ◽  
S. Bikmalla ◽  
A. Thomas
2022 ◽  
Vol 35 (13) ◽  
Author(s):  
Themistoklis Paraskevas ◽  
Eleousa Oikonomou ◽  
Maria Lagadinou ◽  
Vasileios Karamouzos ◽  
Nikolaos Zareifopoulos ◽  
...  

Introduction: Oxygen therapy remains the cornerstone for managing patients with severe SARS-CoV-2 infection and several modalities of non-invasive ventilation are used worldwide. High-flow oxygen via nasal canula is one therapeutic option which may in certain cases prevent the need of mechanical ventilation. The aim of this review is to summarize the current evidence on the use of high-flow nasal oxygen in patients with severe SARS-CoV-2 infection.Material and Methods: We conducted a systematic literature search of the databases PubMed and Cochrane Library until April 2021 using the following search terms: “high flow oxygen and COVID-19” and “high flow nasal and COVID-19’’.Results: Twenty-three articles were included in this review, in four of which prone positioning was used as an adjunctive measure. Most of the articles were cohort studies or case series. High-flow nasal oxygen therapy was associated with a reduced need for invasive ventilation compared to conventional oxygen therapy and led to an improvement in secondary clinical outcomes such as length of stay. The efficacy of high-flow nasal oxygen therapy was comparable to that of other non-invasive ventilation options, but its tolerability is likely higher. Failure of this modality was associated with increased mortality.Conclusion: High flow nasal oxygen is an established option for respiratory support in COVID-19 patients. Further investigation is required to quantify its efficacy and utility in preventing the requirement of invasive ventilation.


2021 ◽  
Author(s):  
Michael Hultström ◽  
Ola Hellkvist ◽  
Lucian Covaciu ◽  
Filip Fredén ◽  
Robert Frithiof ◽  
...  

Abstract Introduction The ratio of partial pressure of arterial oxygen to inspired oxygen fraction (PaO2/FIO2) during invasive mechanical ventilation (MV) is used as criteria to grade the severity of respiratory failure in acute respiratory distress syndrome (ARDS). During the SARS-CoV2 pandemic the use of PaO2/FIO2 ratio has been increasingly used in non-invasive respiratory support such as high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV). The grading of hypoxemia in non-invasively ventilated patients is uncertain. The main hypothesis, investigated in this study, was that the PaO2/FIO2 ratio does not change when switching between MV, NIV and HFNC. Methods This was a sub-study of a single-center prospective observational study of patients admitted to the intensive care unit (ICU) at Uppsala University Hospital in Sweden for critical COVID-19. In a steady state condition, the PaO2/FIO2 ratio was recorded before and after any change between two of the studied respiratory support techniques (i.e., HFNC, NIV and MV). Results A total of 148 patients were included in the present analysis. We find that any change in respiratory support from or to HFNC caused a significant change in PaO2/FIO2 ratio (up to 48 mmHg, from HFNC to MV). Changes in respiratory support between NIV and MV did not show consistent change in PaO2/FIO2 ratio. In patients classified as mild to moderate ARDS during MV, the change from HFNC to MV showed a variable increase in PaO2/FIO2 ratio ranging between 52 and 140 mmHg (median of 127 mm Hg). This made prediction of ARDS severity during MV from the apparent ARDS grade during HFNC impossible. Conclusion HFNC is associated with lower PaO2/FIO2 ratio than either NIV or MV in the same patient, while NIV and MV provided similar PaO2/FIO2 and thus ARDS grade by Berlin definition. The large variation of PaO2/FIO2 ratio precludes using ARDS grade as a measure of pulmonary damage during HFNC.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4082-4082
Author(s):  
Josu de la Fuente ◽  
Subarna Chakravorty ◽  
Rebecca Ayres ◽  
Catherine Mkandawire

Abstract Introduction Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) and a leading cause of hospitalisation and mortality. ACS is defined as a new pulmonary infiltrate on chest radiograph with associated fever or respiratory symptoms. The highest incidence of ACS is in children; occurring in up to 50% in the first decade and peaking in incidence between 2 and 5 years of age. The mainstay of treatment of acute ACS is supportive and clinical management of ACS varies between centres in the type of blood transfusion (top-up versus exchange), post transfusion percentage sickle cells (HbS%); type of ventilatory support and guidelines regarding escalation of care. Additionally, there are controversies in the use of bronchodilators and corticosteroids in the acute management of ACS. To allow trials to be undertaken, it is important to first assess the current practice of the acute management of ACS in children across paediatric centres in the UK and Europe. Methods An electronic survey was devised based on the currently available literature on management of children with ACS. The survey was sent to major centres in the UK, France, Ireland, Netherlands and Belgium who are involved in clinical management of Paediatric SCD. A retrospective single-centre audit of the management of Paediatric ACS was also undertaken in the researchers’ institution over a 24-month period. Results 1. Multinational survey The survey was sent to 48 centres of which 20 centres responded (38%). 68% (n=13), of centres treat less than 10 cases of ACS per year. There was variation in diagnostics (table 1), use of incentive spirometry, fluids and antimicrobials (table 2), indications for transfusion (table 3) and in the escalation of care (table 4) between centres. *Denotes more than one answer to each question Table 1.–DiagnosisTable 1. –Diagnosis Table 2 – Intervention n % of centres Incentive spirometry given Yes 15 75 No 5 25 Fluid given 80% 1 5 100% 14 70 150% 4 20 Antibiotics routinely prescribed to treat ACS* Clarithromycin 16 Cefuroxime 11 Ceftriaxone 6 Co-amoxiclav 3 Are antivirals prescribed? Yes 6 31 No 13 68 When are bronchodilators given* To wheezy patients 10 To all patients with ACS 6 Asthmatics 4 Not routinely given 3 Are corticosteroids routinely given Yes 1 5 No 17 85 Only to known asthmatics 2 10 Table 3 – Transfusion n % Indication for transfusion in patients with ACS* Worsening anaemia with respiratory symptoms 17 Worsening respiratory symptoms 12 O2 saturations 3% below usual baseline 7 Target post transfusion HbS% <20% 2 10 <30% 14 73 <50% 3 15 Table 4 – Escalation of care n % of centres Indication for non-invasive ventilation (NIV)* Worsening hypoxia 15 75 Severe dyspnoea 13 65 Increasing hypercapnia causing respiratory acidosis 11 55 Centre does not offer NIV 4 20 Mode of respiratory support offered* High flow oxygen 14 70 Continuous positive airway pressure (CPAP) 10 50 Optiflow TM 7 35 Other (CNEP, BiPAP) 3 15 Unknown 1 5 2. Single-centre retrospective audit Forty-six patients were admitted to St Mary’s Hospital with ACS during the period of the study. The median age was 10 years. Ninety per cent (n=36) of patients had a chest x-ray on admission. The average Hb on admission was 76 g/L. Eighty-nine per cent (n=33) of patients had blood cultures taken on admission; of which two were positive (Acinetobacter and Micrococcus spp). Non-invasive ventilation was given to 47% (n=18) of patients. Forty-two per cent (n=24) of patients were given at least one blood transfusion with average post-transfusion HbS% of 28.5. Conclusion This study reflects a wide variation in management of ACS in centres across the UK and Europe, with a focused audit of one centre in London. Consensus was reached in provision of incentive spirometry and antibiotic use, but practice varied widely in indications for blood transfusion, anti-viral agents and bronchodilators. A multi-centre prospective trial is therefore required in ACS management to establish optimum management based on patient outcome. Disclosures No relevant conflicts of interest to declare.


Healthcare ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 145 ◽  
Author(s):  
Samuel Trethewey ◽  
Ross Edgar ◽  
Alice Turner ◽  
Rahul Mukherjee

Non-invasive ventilation (NIV) is frequently used as a treatment for acute hypercapnic respiratory failure (AHRF) in hospitalised patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). In the UK, many patients with AHRF secondary to AECOPD are treated with ward-based NIV, rather than being treated in critical care. NIV has been increasingly used as an alternative to invasive ventilation and as a ceiling of treatment in patients with a ‘do not intubate’ order. This narrative review describes the evidence base for ward-based NIV in the context of AECOPD and summarises current practice and clinical outcomes in the UK.


2020 ◽  
Author(s):  
Antonio Gidaro ◽  
Federica Samartin ◽  
Anna Maria Brambilla ◽  
Chiara Cogliati ◽  
Stella Ingrassia ◽  
...  

Background: Acute Hypoxemic Respiratory Failure (AHRF) is a common complication of Covid-19 related pneumonia, for which non-invasive ventilation (NIV) with Helmet Continuous Positive Airway Pressure (CPAP) is widely used. During past epidemics of SARS and MERS pneumomediastinum (PNM) and pneumothorax (PNX) were common complications (respectively 1.7-12% and 16,4%) either spontaneous or associated to ventilation. Methods: Aim of our retrospective study was to investigate the incidence of PNX/PNM in COVID-19 pneumonia patients treated with CPAP. Moreover, we examined the correlation between PNX/PNM and Positive end-expiratory pressure (PEEP) values. We collected data from patients admitted to Luigi Sacco University Hospital of Milan from 21/02/2020 to 06/05/2020 with COVID-19 pneumonia requiring CPAP. Results: One-hundred-fifty-four patients were enrolled. During hospitalization 3 PNX and 2 PNM occurred (3.2%). Out of these five patients 2 needed invasive ventilation after PNX, two died. In the overall population, 42 patients (27%) were treated with High-PEEP (>10 cmH2O), and 112 with Low-PEEP (≤10 cmH2O). All the PNX/PNM occurred in the High-PEEP group (5/37 vs 0/112, p<0,001). Conclusion: The incidence of PNX appears to be lower in COVID-19 than SARS and MERS, but their occurrence is accompanied by high mortality and worsening of clinical conditions. Considering the association of PNX/PNM with high PEEP we suggest using the lower PEEP as possible to prevent these complications.


Author(s):  
Anita Saigal ◽  
Amar J Shah ◽  
Swapna Mandal

Acute hypercapnic respiratory failure accounts for 50 000 hospital admissions each year in the UK. This article discusses the pathophysiology and common causes of acute hypercapnic respiratory failure, and provides practical considerations for patient management in acute medical settings. Non-invasive ventilation for persistent acute hypercapnic respiratory failure is widely recognised to improve patient outcomes and reduce mortality. National audits highlight a need to improve patients' overall care and outcomes through appropriate patient selection and treatment initiation. Multidisciplinary involvement is essential, as this underpins inpatient care and follow up after hospital discharge. New non-invasive ventilation modalities may offer better patient comfort and compensate better for sleep-related changes in respiratory mechanics. Emerging therapies, such as nasal high flow, may offer an alternative treatment approach in those who cannot tolerate non-invasive ventilation, but more research is required to completely understand its effectiveness in treating acute hypercapnic respiratory failure.


Thorax ◽  
2016 ◽  
Vol 71 (Suppl 3) ◽  
pp. A126.1-A126
Author(s):  
SJ Tetlow ◽  
PS Marino ◽  
PD Murphy ◽  
H Pattani ◽  
J Steier ◽  
...  

2019 ◽  
Vol 18 (5) ◽  
pp. 665-670 ◽  
Author(s):  
Olga Archangelidi ◽  
Siobhán B. Carr ◽  
Nicholas J. Simmonds ◽  
Diana Bilton ◽  
Winston Banya ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document